Spyre Therapeutics (SYRE) Cash from Financing Activities (2015 - 2026)

Spyre Therapeutics has reported Cash from Financing Activities for 12 years, with the latest figure at $12.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 9704.0% year-over-year to $12.3 million; the trailing twelve-month figure through Mar 2026 stood at $321.2 million (up 34.45% YoY), and the FY2025 full-year result was $309.0 million, down 24.79% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $12.3 million, down from $312.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $312.8 million in Q4 2025, with the low at -$12.5 million in Q3 2023.
• Historically, Cash from Financing Activities has averaged $66.8 million across 5 years, with a median of $731000.0 in 2025.
• The largest YoY upside for Cash from Financing Activities was 2045175.0% in 2023 against a maximum downside of 9539.23% in 2023.
• Spyre Therapeutics' Cash from Financing Activities stood at -$8000.0 in 2022, then soared by 2045175.0% to $163.6 million in 2023, then surged by 37.89% to $225.6 million in 2024, then jumped by 38.66% to $312.8 million in 2025, then tumbled by 96.08% to $12.3 million in 2026.
• The last three Cash from Financing Activities figures came in at $12.3 million (Q1 2026), $312.8 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.